New appointment at DxS
This article was originally published in Scrip
The UK personalised medicine company DxS has named Dr David Jackson vice-president of business development and licensing. He will be responsible for business development efforts for the companion diagnostics and technology licensing business units of DxS and will be based in the US. Dr Jackson was most recently executive vice-president at Response Genetics. Before that, he was president and chief operating officer at CryoFluor Therapeutics.